Astilbin ameliorates experimental autoimmune myasthenia gravis by decreased Th17 cytokines and up-regulated T regulatory cells.
Astilbin, a major bioactive compound extracted from Rhizoma smilacis glabrae (RSG), has been reported to possess immunosuppressive properties. Our study first evaluated the effect of astilbin on experimental autoimmune myasthenia gravis (EAMG) in Lewis rats. The results showed that astilbin could attenuate the severity of EAMG by decreasing antigen-specific autoantibodies with up-regulation of regulatory T cells and down-regulation of Th17 cells. In addition to, astilbin also reduced the efficiency of the antigen presenting cells on which the expression of MHC class II decreased. These results suggest that astilbin might be a candidate drug for immunoregulation of EAMG, and provide us new treatment ideas for human myasthenia gravis (MG).
Department of Neurology, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250001, PR China.
Qing-Fang
QF
Meng
Department of Emergency, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250001, PR China.
Zheng
Z
Zhang
Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, PR China.
Yan-Jun
YJ
Wang
Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, PR China.
Wei
W
Chen
Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, PR China.
Fei-Fei
FF
Li
Central Laboratory, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, PR China.
Long-Tao
LT
Yue
Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, PR China.
Chang-Jun
CJ
Zhang
Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, PR China.
Heng
H
Li
Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, PR China.
Min
M
Zhang
Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, PR China.
Cong-Cong
CC
Wang
Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, PR China.
Peng
P
Zhang
Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, PR China.
Hui
H
Chen
Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, PR China.
Rui-Sheng
RS
Duan
Department of Traditional Chinese Medicine, Shandong Provincial Qianfoshan Hospital, Jinan 250014, PR China.
Shan-Mei
SM
Sun
Department of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, PR China. Electronic address: lch1226@sohu.com.
Yan-Bin
YB
Li
D000704:Analysis of Variance; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D015703:Antigens, CD / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D016207:Cytokines / Q000378:metabolism*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D044948:Flavonols / Q000494:pharmacology* / Q000627:therapeutic use*; D005434:Flow Cytometry; D059805:HLA-DR alpha-Chains / Q000378:metabolism; D020720:Myasthenia Gravis, Autoimmune, Experimental / Q000188:drug therapy* / Q000276:immunology*; D051381:Rats; D011917:Rats, Inbred Lew; D012844:Sincalide / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects*; D058504:Th17 Cells / Q000187:drug effects*
D000893:Anti-Inflammatory Agents; D015703:Antigens, CD; D016207:Cytokines; D044948:Flavonols; D059805:HLA-DR alpha-Chains; C099069:astilbin; D012844:Sincalide
Astilbin; Experimental autoimmune myasthenia gravis; MHC class II; Th cells; Th17 cells